Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.960-1.060 for the period, compared to the consensus earnings per share estimate of 0.970. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Analysts Set New Price Targets

AMRX has been the topic of several research reports. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. UBS Group boosted their price objective on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Barclays lifted their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.33.

Amneal Pharmaceuticals Trading Down 1.6%

NASDAQ AMRX traded down $0.29 on Friday, reaching $18.21. The stock had a trading volume of 788,818 shares, compared to its average volume of 2,171,289. Amneal Pharmaceuticals has a 1 year low of $7.66 and a 1 year high of $19.26. The business has a 50 day moving average price of $16.11 and a 200 day moving average price of $14.23. The company has a market capitalization of $5.81 billion, a price-to-earnings ratio of 47.91 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.03. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, analysts anticipate that Amneal Pharmaceuticals will post 0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 17.30% of the company’s stock.

Key Stories Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 earnings beat expectations: Amneal reported $796 million in revenue, $58 million in GAAP net income, and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus and up from $0.25 a year earlier. Adjusted EBITDA reached $206 million. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Amneal now expects 2026 revenue of $3.1 billion to $3.2 billion and EPS of $0.96 to $1.06. The EPS midpoint of $1.01 is above the roughly $0.97 consensus estimate, while the revenue range is generally in line with expectations. Amneal Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Lower financing costs should support profits: The company successfully repriced its debt in July, a move expected to reduce interest expense and improve cash flow and earnings going forward. Amneal Q2 2026 Earnings Call Transcript
• Neutral Sentiment: GAAP diluted EPS was $0.18, below the $0.30 adjusted figure, and the company continues to report a low net margin and negative return on equity. Investors may therefore focus on adjusted earnings growth and debt reduction when assessing the results. Amneal Q2 2026 Earnings Call Transcript

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP boosted its stake in shares of Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after buying an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Amneal Pharmaceuticals by 3.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock valued at $70,681,000 after acquiring an additional 177,906 shares during the period. Morgan Stanley boosted its position in shares of Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after acquiring an additional 1,315,018 shares during the period. Nantahala Capital Management LLC boosted its holdings in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after purchasing an additional 558,877 shares during the period. Finally, State Street Corp grew its position in Amneal Pharmaceuticals by 3.4% during the fourth quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after buying an additional 136,662 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.